Fernand Labrie

Publications

Page 7 of 26, showing 50 records out of 1263 total, starting on record 301, ending on 350

Publication Category Year
128. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29-37. All publications 1994
115. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1995) Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 23: 149-156. All publications 1995
4692. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Bélanger, A., Vandenput, L., Mellström, D., Ohlsson, C. (2009) Comparable Amounts of Sex Steroids are Made Outside the Gonads in Men and Women: Strong Lesson for Hormone Therapy of Prostate and Breast Cancer, JSBMB, 113: 52-56. All publications 2009
556. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Chaussade, V., Deloche, C., Leclaire, J. (2008) Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol, 110: 1-9. All publications 2008
624. Labrie, F., Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Candas, B. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab., 82: 3498-3505. All publications 1997
490. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Béland, Y., Cusan, L., Lachance, R. (1990) Complete response to combination therapy with an LHRH agonist and Flutamide in metastatic male breast cancer: a case report. Clin. Invest. Med., 13: 275-278. All publications 1990
173. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1990) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J. Steroid Biochem. Mol. Biol., 37: 943-950. All publications 1990
150. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1992) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer (8-year clinical experience) and extension to early stages of the diseases, in: Carpi, A., Sagripanti, A. et Mittermayer, eds: Progress in Clinical Oncology, Italy, Sympomed Verlag, pp 278-293. All publications 1992
3924. Labrie, F., Dupont, A., Cusan, L., Gomez, J.-L., Diamond, P. (1993) Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med., 16: 493-498. All publications 1993
142. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Tetu, B., Emond, J., Candas, B. (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with Flutamide and Lupron. Clin. Invest. Med., 16: 499-509. All publications 1993
103. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Surubu, R., Diamond, P. (1996) Combination therapy with Flutamide: The therapy of choice from early to advanced stages of prostate cancer, in: Denis, L., ed. Antiandrogens in Prostatic Cancer, Italy, European School of Oncology, pp 63-74. All publications 1996
4039. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Lacourcière, Y., Monfette, G., Emond, J. (1990) Maximal androgen blockade in prostate cancer: Today's therapy of choice and 5-year clinical experience. In: Vickery, B.H. et Lunenfeld, B., eds. International Symposium on GnRH analogues in Cancer and Human Reproduction. III: pp 79-102. All publications 1990
151. Labrie, F., Dupont, A., Cusan, L., Suburu, E.R., Gomez, J.L., Thibault, M.M., Tremblay, M. (1992) Perspectives dans le diagnostic et le traitement du cancer de la prostate au stade précoce, in: Bonjour, J.P., Gayraud, M.,Guillevin, L. et Rizzoli, R., eds: Nouvelles statégies thérapeutiques en cancérologie, rapports présentés au XLVIIIe Congrès Français de Médecine, Montréal 1991, Alertes carcinologiques, pp 25-44. All publications 1992
143. Labrie, F., Dupont, A., Simard, J., Luu-The, V., Bélanger, A. (1993) Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol., 24 Suppl. 2: 94-105. All publications 1993
144. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Gomez, J.L., Koutsilieris, M., Diamond, P., Emond, J., Lemay, M., Candas, B. (1993) Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin. Invest. Med., 16: 425-439. All publications 1993
152. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., Emond, J. (1992) Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 147: 846-851. All publications 1992
390. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. All publications 2003
725. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. All publications 2008
400. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. All publications 2001
396. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. All publications 2002
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. All publications 1999
401. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. All publications 2001
409. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. All publications 2000
469. Labrie, F., Li, S., Bélanger, A., Côté, J., Mérand, Y., Lepage, M. (1993) Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethylbenz(a)anthracene in the rat. Breast Cancer Res. Treat., 26: 253-265. All publications 1993
459. Labrie, F., Li, S., Labrie, C., Lévesque, C., Mérand, Y. (1995) Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 33: 237-244. All publications 1995
20. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. All publications 2005
3555. Labrie, F., Luu-The, V., Calvo, E., Martel, C., Cloutier, J., Gauthier, S., Belleau, P., Boucher, H., Morissette, J., Lévesque, M.H., Labrie, C. (2005) Tetrahydrogestrione (THG) induces a genomic signature typical of a potent anabolic steroid. J Endocrinol, 184: 427-33. All publications 2005
391. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews, 24 (2): 152-182. All publications 2003
359. Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., El Alfy, M. (2000) Intracrinology and the skin. Horm. Res., 54: 218-229. All publications 2000
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. All publications 2001
855. Labrie, F., Luu-The, V., Lin, S.-X., Labrie, C., Simard, J., Breton, R., Bélanger, A. (1997) The key role of 17beta-HSDs in sex steroid biology. Steroids, 62: 148-158. All publications 1997
50. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. All publications 2000
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. All publications 2000
578. Labrie, F., Luu-The, V., Martel, C., Chernomoretz, A., Calvo, E., Morissette, J., Labrie, C. (2006) Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol, 100: 52-8. All publications 2006
4705. Labrie, F., Martel, C. (2009) Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment? The Lancet - Reflection and Reaction, 10: 444-445 All publications 2009
4712. Labrie, F., Martel, C., Gauthier, S., Pelletier, G., Sancéau JY. (2010) Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues, Horm Mol Biol Clin Invest, 1: 139-146. All publications 2010
1097. Labrie, F., Poulin, R., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (2006) Androgens, DHEA and Breast Cancer, in: Tulandi, T. et Gelfand, M.M., eds: Androgens and Reproductive Aging, Oxsfordshire, UK, pp 113-135. All publications 2006
491. Labrie, F., Poulin, R., Simard, J., Zhao, H., Labrie, C., Dauvois, S., Dumont, M., Hatton, A.C., Poirier, D., Mérand, Y. (1990) Interactions between estrogens, androgens, progestins and glucocorticoids in ZR-75-1 human breast cancer cells. in: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. N.Y. Acad. Sci. 595: 130-148. All publications 1990
403. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. All publications 2001
3800. Labrie, F., Simard, J., Bélanger, A., Lin, S.-X., Luu-The, V., Labrie, F. (1996) Cancer: What are the role and sources of steroid hormones and the possible role of adipose tissue? In: Angel, A., Anderson, H., Bouchard, C., Lau, D., Leiter, L. et Mendelson, R., eds: Progress in Obesity Research: 7, London, John Libbey & Company Ltd., pp 559-567. All publications 1996
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. All publications 1994
85. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. All publications 1997
474. Labrie, F., Simard, J., de Launoit, Y., Poulin, R., Thériault, C., Dumont, M., Dauvois, S., Martel, C., Li, S.; (1992) Androgens and breast cancer. Cancer Detect. Prev., 16: 31-38. All publications 1992
3990. Labrie, F., Simard, J., Luu-The, V., Bélanger, A., Cusan, L., Dupont, A., Trudel, C., Martel, C., Labrie, C., Zhao, H.F., Dupont, E., Couet, J., Lachance, Y., Dumont, M., de Launoit, Y., Breton, N. (1991) Androgens in post-menopause, in: Rivista di Ostetricia e Ginecologia Pratica e Medicina Perinatale, Palermo, pp 15-24. All publications 1991
978. Labrie, F., Simard, J., Luu-The, V., Bélanger, A., Pelletier, G. (1992) Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J. Steroid Biochem. Mol. Biol., 43: 805-826. All publications 1992
884. Labrie, F., Simard, J., Luu-The, V., Bélanger, A., Pelletier, G., Morel, Y., Mebarki, F., Sanchez, R., Durocher, F., Turgeon, C., Labrie, Y., Rhéaume, E., Labrie, C., Lachance, Y. (1996) The 3beta-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3beta-HSD congenital deficiency, in: Proceeding 9th European Testis Workshop Signal Transduction in Testicular Cells - Basic and Clinical Aspects, Springer-Verlag, pp 185-218. All publications 1996
934. Labrie, F., Simard, J., Luu-The, V., Pelletier, G. (1994) Molecular genetics, structure-function relationships and tissue-specific expression and tissue-specific expression and regulation of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family, in: Bartke, A., ed. Function of Somatic Cells in the Testis, New York, NY, USA, Springer-Verlag, pp 126-150. All publications 1994
979. Labrie, F., Simard, J., Luu-The, V., Pelletier, G., Bélanger, A. (1992) Cloning, expression and regulation of tissue-specific expression of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in Cellular and Molecular Biology of the Adrenal Cortex, London, John Libbey Eurotext Ltd., pp 89-109. All publications 1992
980. Labrie, F., Simard, J., Luu-The, V., Pelletier, G., Bélanger, A., Lachance, Y., Zhao, H.F., Labrie, C., Breton, N., de Launoit, Y., Dumont, M., Dupont, E., Rhéaume, E., Martel, C., Couët, J., Trudel, C. (1992) Structure and tissue-specific expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J. Steroid Biochem. Mol. Biol., 41: 421-435. All publications 1992
935. Labrie, F., Simard, J., Luu-The, V., Pelletier, G., Belghmi, K., Bélanger, A. (1994) Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in formation of sex steroids in classical and peripheral intracrine tissues, in: Sheppard, M.C. et Stewart, P.M., eds: Hormones, Enzymes and Receptors, London, Baillière's clinical endocrinology and metabolism, pp 451-474. All publications 1994
<< previous | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards